MammaPrint^® is a tool designed to help to predict clinical outcome in breast cancer. MammaPrint^® predicts the risk of metastasis in breast cancer patients. It is based on groundbreaking research performed at the Netherlands Cancer Institute and the Antoni Van Leeuwenhoek Hospital in Amsterdam, The Netherlands.

Note: MammaPrint^® analysis cannot be performed on formalin-fixed paraffin embedded (FFPE) tumor tissue as this fixation procedure causes the RNA to degrade. The high accuracy of MammaPrint^® depends on keeping the tumor RNA intact.

MammaPrint^® is a service from Agendia, Slotervaart Hospital, Amsterdam, Holland. Distributed and commercialized in Spain by Ferrer inCode